126 related articles for article (PubMed ID: 21536390)
1. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
3. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
[No Abstract] [Full Text] [Related]
4. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
5. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
6. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
7. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
Formica V; Roselli M
World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor in CRC patients in the era of the RAS.
Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation testing in colorectal cancer.
Plesec TP; Hunt JL
Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
[TBL] [Abstract][Full Text] [Related]
12. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
14. Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.
Yin P; Qiu Y; Li Q
Int J Colorectal Dis; 2013 May; 28(5):733-4. PubMed ID: 22752244
[No Abstract] [Full Text] [Related]
15. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
18. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
19. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
